Clearmind Dividend Paid And Capex Coverage Ratio from 2010 to 2024
| CMND Stock | USD 1.30 0.02 1.56% |
Dividend Paid And Capex Coverage Ratio | First Reported 2010-12-31 | Previous Quarter (769.93) | Current Value (731.44) | Quarterly Volatility 323.87044263 |
Check Clearmind Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Clearmind Medicine's main balance sheet or income statement drivers, such as Interest Expense of 21.5 K, Selling General Administrative of 8 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.51. Clearmind financial statements analysis is a perfect complement when working with Clearmind Medicine Valuation or Volatility modules.
Clearmind | Dividend Paid And Capex Coverage Ratio |
Latest Clearmind Medicine's Dividend Paid And Capex Coverage Ratio Growth Pattern
Below is the plot of the Dividend Paid And Capex Coverage Ratio of Clearmind Medicine Common over the last few years. It is Clearmind Medicine's Dividend Paid And Capex Coverage Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Clearmind Medicine's overall financial position and show how it may be relating to other accounts over time.
| Dividend Paid And Capex Coverage Ratio | 10 Years Trend |
|
Dividend Paid And Capex Coverage Ratio |
| Timeline |
Clearmind Dividend Paid And Capex Coverage Ratio Regression Statistics
| Arithmetic Mean | (192.64) | |
| Coefficient Of Variation | (168.12) | |
| Mean Deviation | 275.97 | |
| Median | (0.80) | |
| Standard Deviation | 323.87 | |
| Sample Variance | 104,892 | |
| Range | 769 | |
| R-Value | (0.78) | |
| Mean Square Error | 43,967 | |
| R-Squared | 0.61 | |
| Significance | 0.0006 | |
| Slope | (56.60) | |
| Total Sum of Squares | 1.5M |
Clearmind Dividend Paid And Capex Coverage Ratio History
About Clearmind Medicine Financial Statements
Clearmind Medicine stakeholders use historical fundamental indicators, such as Clearmind Medicine's Dividend Paid And Capex Coverage Ratio, to determine how well the company is positioned to perform in the future. Although Clearmind Medicine investors may analyze each financial statement separately, they are all interrelated. For example, changes in Clearmind Medicine's assets and liabilities are reflected in the revenues and expenses on Clearmind Medicine's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Clearmind Medicine Common. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Dividend Paid And Capex Coverage Ratio | (769.93) | (731.44) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Clearmind Medicine Common is a strong investment it is important to analyze Clearmind Medicine's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearmind Medicine's future performance. For an informed investment choice regarding Clearmind Stock, refer to the following important reports:Check out the analysis of Clearmind Medicine Correlation against competitors. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearmind Medicine. If investors know Clearmind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearmind Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.23) | Return On Assets (0.58) | Return On Equity (2.68) |
The market value of Clearmind Medicine Common is measured differently than its book value, which is the value of Clearmind that is recorded on the company's balance sheet. Investors also form their own opinion of Clearmind Medicine's value that differs from its market value or its book value, called intrinsic value, which is Clearmind Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearmind Medicine's market value can be influenced by many factors that don't directly affect Clearmind Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearmind Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearmind Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearmind Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.